Published Date: 24 Jul 2025
A new study has explored how people with hereditary cancer identify on TikTok.
Read Full NewsHere's some of what is coming soon to NeurologyLive® this week.
Encouraging data from the OCEANIC-STROKE study suggest that asundexian may soon join the therapeutic landscape for secondary stroke prevention as Bayer advances toward submission.
Benjamin Locksin speaks in this interview about his session titled ‘Encapsulating Progress With New and Emerging TYK2 Inhibitors for Psoriasis.’
After his sessions on TYK2 Inhibitors for psoriasis and on palmoplantar pustulosis, Vender discussed several key insights in this interview.
FDA Clears BrainsWay’s TMS Device for Adolescents with MDD Aged 15 to 21 Years
Adjunctive Perospirone Safe, Well-Tolerated for MDD in Phase 4 Trial
Otsuka Pharmaceuticals Submits NDA for Centanafadine to Treat ADHD in Children
1.
Additional Proof of the Different Cognitive Effects of ARSIs for Prostate Cancer.
2.
Year in Review: Chronic Lymphocytic Leukemia
3.
In a long-term comparison with adjuvant RT, salvage radiotherapy after prostateectomy is the most successful treatment.
4.
CAR T-Cell Therapy in Functional High-Risk Multiple Myeloma
5.
Response Duration After Stopping Enfortumab Vedotin in Bladder Cancer
1.
Understanding Blood Dyscrasia: Symptoms, Causes and Treatment Options
2.
AI-Driven Chemotherapy: Transforming Cancer Care with Precision and Efficiency
3.
Rare Malignant Ovarian Tumors: A Comprehensive Review for Clinicians
4.
Early-Onset GI Cancers: Screening, AI Innovations & Research Advances 2025
5.
Unleashing the Power of AI: A Systematic Review of Predictive Biomarker Discovery in Immuno-Oncology
1.
International Lung Cancer Congress®
2.
Genito-Urinary Oncology Summit 2026
3.
Future NRG Oncology Meeting
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
Molecular Contrast: EGFR Axon 19 vs. Exon 21 Mutations - Part V
2.
Navigating the Complexities of Ph Negative ALL - Part VII
3.
The Landscape of First-Line Treatment for Urothelial Carcinoma- Further Discussion
4.
Expert Group meeting with the management of EGFR mutation positive NSCLC - Part III
5.
An Eagles View - Evidence-based discussion on Iron Deficiency Anemia- Important Points to Know
© Copyright 2025 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation